FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| 1. Name and Address of Reporting Person* Frey Travis (Last) (First) (Last) (First) (Street) ROSEVILLE MN (City) (State) (Zip) | | | | | 2. Issuer Name and Ticker or Trading Symbol Cibus, Inc. [CLXT] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023 4. If Amendment, Date of Original Filed (Month/Day/Year) Rule 10b5-1(c) Transaction Indication | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Technology Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
|---|--------|--|--|------------------|---|---------|---|------------------|---|--------------------|---------------------------|-------------------------------------|---|--|--|-----------|---|
| | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | |
| 4 Title : (| C | | able I - Nor | | | | | | Disp | | , | - | | | 6.0 | | 7. Nature of |
| | | | | Date | 2. Transaction Date (Month/Day/Year) | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | | | Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership |
| | | | | | | | | | v | Amount | (A) or (D) | Price | Reported Transactio (Instr. 3 a | | | | (Instr. 4) |
| Common Stock 05/3 | | | | 05/31/ | 1/2023 | | A | | 5,733 ⁽¹ | ¹⁾ A | \$0 ⁽¹⁾ | 19,0 | 19,060 ⁽¹⁾ | | D | | |
| | | | Table II - | | | | | | | osed of, o | | | wned | | | | |
| Derivative Conversion Date | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Dat if any (Month/Day/Ye | Code | Transaction Code (Instr. | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisal Expiration Date (Month/Day/Year | | e of Securities | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securitie Beneficia Owned Following | e Ownersh s Form: Illy Direct (D or Indire g (I) (Instr. | Ownership | Beneficial Ownership ct (Instr. 4) |
| | | | | Code | • v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | Amount or Number of Shares | | Reported Transacti (Instr. 4) | | | |
| Stock Option (Right-to- Buy) | \$4.55 | 03/01/2023 | | D ⁽²⁾ |) | | 80,000 | (2) | | 08/04/2030 | Common Stock | 80,000 | (2) | 0 | | D | |
| Stock Option (Right-to- Buy) | \$4.55 | 03/01/2023 | | A ⁽² | | 80,000 | | (2) | | 08/04/2030 | Common Stock | 80,000 | (2) | 80,00 |)0 | D | |
| Stock Option (Right-to- Buy) | \$8.05 | 03/01/2023 | | D ⁽² | | | 24,000 | (2) | | 03/12/2031 | Common Stock | 24,000 | (2) | 0 | | D | |
| Stock Option (Right-to- Buy) | \$8.05 | 03/01/2023 | | A ⁽²⁾ | | 24,000 | | (2) | | 03/12/2031 | Common Stock | 24,000 | (2) | 24,00 | 00 | D | |
| Stock Option (Right-to- Buy) | \$1.27 | 03/01/2023 | | D ⁽² |) | | 250,000 | (2) | | 03/24/2032 | Common Stock | 250,000 | (2) | 0 | | D | |
| Stock Option (Right-to- Buy) | \$1.27 | 03/01/2023 | | A ⁽²⁾ | | 250,000 | | (2) | | 03/24/2032 | Common Stock | 250,000 | (2) | 250,00 | 00 | D | |

Explanation of Responses:

1. Shares were received for no consideration upon the satisfaction of performance criteria underlying the award of the performance share units. Shares reflect the one-for-ten reverse stock split effected on April 24, 2023 and the one-for-five reverse stock split effected on May 31, 2023.

2. The reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split effective on May 31, 2023. Amounts reported above are pre-split.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.